“New treatment options continue to be needed for patients with ROS1 fusion-positive NSCLC that support important clinical goals, including achieving durable therapeutic responses,” said ...

Bristol Myers Squibb (NYSE:BMY) has received a recommendation for approval from the Committee for Medicinal Products for ...

Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.

Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...

EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...

The Princeton, N.J., biopharmaceutical company said the recommendation cover Augtyro as a treatment for adults with ROS1-positive advanced ... expressing a NTRK gene fusion. The European ...